Refutable Rates - Applied Clinical Trials

ADVERTISEMENT

pagepush
See our 2009 Buyers Guide Digital Edition.
Find Pharma Search Engine
Refutable Rates

Source: Applied Clinical Trials

Perhaps few issues elicit more interest in clinical trial agreements (clinical grants) than the overhead portion of the contract. Clinical trial agreements typically have three parts: procedures, nonprocedures, and overhead.

Procedures are those medical activities directly related to the protocol that may range from a blood draw to something far more complex. Nonprocedures include an equally broad range of activities, such as study coordinator time, facility charges, patient reimbursement, and meals.

Overheads are indirect institutional costs allocated to individual departments and their programs. These indirect costs can include such illustrative items as costs of the institution's general management, building maintenance, general administration, and in some cases, general marketing efforts.

Here we report U.S. overhead rates. Few pharmaceutical companies are willing to pay overhead costs to office-based investigators. However, most clinical trial agreements with institutions include an overhead figure.


Instiutions vs Actual Agreements in U.S.-Based Overhead Figures
Clinical grant data in GrantPlan from companies conducting 76% of all clinical studies demonstrate that, in general, overheads at academic medical centers are slightly higher than at other institutions.

Particularly noteworthy though is the significant difference between the overhead rate reported by the institution, frequently used as the starting point in negotiations, and the actual amount accepted in the contract by the institution.—TTC (For more information, please contact
.)

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.

ADVERTISEMENT

FindPharma
Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
93%
Borrow lightly from EMA's pathway program?
0%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here